|
|
|
|
在研适应症- |
非在研适应症- |
最高研发阶段临床1期 |
首次获批国家/地区- |
首次获批日期- |
靶点- |
作用机制- |
|
|
在研适应症- |
非在研适应症- |
最高研发阶段临床1期 |
首次获批国家/地区- |
首次获批日期- |
Double-blind, Randomized, Dose-response Study of RE02 in Healthy Subjects
The goal of this clinical trial is to compare corresponding inter- and intraindividual pharmacokinetic and pharmacodynamic profiles including assessments of safety & tolerability of three different doses against a placebo control.
Single-blind, Randomized, Two-arm, Dose-response Study of DMT and Harmine in Healthy Subjects
The goal of this clinical trial is to compare corresponding inter- and intraindividual pharmacokinetic and pharmacodynamic profiles including assessments of safety & tolerability.
100 项与 Reconnect Labs 相关的临床结果
0 项与 Reconnect Labs 相关的专利(医药)
100 项与 Reconnect Labs 相关的药物交易
100 项与 Reconnect Labs 相关的转化医学